Philip Nizza, DO
Infectious Disease · East Setauket, NYNPI 1912012410
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,530 of the $15,951 with a category attached, or 78.6%. 7 manufacturers reported payments, led by Merck at 50.6% of the total. Reporting peaked in 2019 at $9,112 and has fallen 97.5% since, to $230 in 2025. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $194.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8K
- AbbVie$8K
- Cumberland Pharmaceuticals, Inc.$130
- Tetraphase Pharmaceuticals, Inc.$51
- Melinta Therapeutics, LLC$47
- Gilead$14
- plus $14 from 1 others
What the payments were for
- Speaking & faculty fees$12,53079%
- Travel & lodging$1,1067%
- Food & beverage$2,29014%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 22 | $8,065 |
| AbbVie(2 entities) | 46 | $7,631 |
| Cumberland Pharmaceuticals, Inc. | 7 | $130 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $51 |
| Melinta Therapeutics, LLC | 2 | $47 |
| Gilead | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,951 in reported general payments places this provider in the 90th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 25 | $45,567 |
| Fosfomycin Tromethamine | 15 | $14,106 |
| ErtapenemErtapenem Sodium | 29 | $13,629 |
| Vancomycin Hcl | 23 | $4,499 |
| CeftriaxoneCeftriaxone Sodium | 24 | $2,368 |
| Cefepime Hcl | 11 | $2,017 |
| Cefazolin Sodium | 15 | $1,019 |
| Cephalexin | 21 | $558 |
| Doxycycline Hyclate | 17 | $535 |
| Minocycline Hcl | 22 | $460 |
| Cefadroxil | 17 | $381 |
| Amoxicillin | 16 | $246 |
| Ciprofloxacin Hcl | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in East Setauket
- David GalinkinEast Setauket$17K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Andre BrutusBrooklyn$303K
- Stephen ThomasSyracuse$294K
- Glenn TurettFlushing$253K
- Genovefa PapanicolaouNew York$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.